Browse SLC22A3

Summary
SymbolSLC22A3
Namesolute carrier family 22 (organic cation transporter), member 3
Aliases solute carrier family 22 (extraneuronal monoamine transporter), member 3; EMTH; EMT organic cation transport ......
Chromosomal Location6q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane; Multi-pass membrane protein.
Domain PF07690 Major Facilitator Superfamily
Function

Mediates potential-dependent transport of a variety of organic cations. May play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.

> Gene Ontology
 
Biological Process GO:0001504 neurotransmitter uptake
GO:0001505 regulation of neurotransmitter levels
GO:0006836 neurotransmitter transport
GO:0006855 drug transmembrane transport
GO:0009991 response to extracellular stimulus
GO:0015695 organic cation transport
GO:0015697 quaternary ammonium group transport
GO:0015844 monoamine transport
GO:0015850 organic hydroxy compound transport
GO:0015872 dopamine transport
GO:0015893 drug transport
GO:0031667 response to nutrient levels
GO:0032098 regulation of appetite
GO:0042493 response to drug
GO:0045117 azole transport
GO:0051608 histamine transport
GO:0051615 histamine uptake
GO:0051937 catecholamine transport
GO:0098657 import into cell
GO:1901998 toxin transport
Molecular Function GO:0005329 dopamine transmembrane transporter activity
GO:0008504 monoamine transmembrane transporter activity
GO:0015101 organic cation transmembrane transporter activity
GO:0015651 quaternary ammonium group transmembrane transporter activity
GO:0019534 toxin transporter activity
GO:0022804 active transmembrane transporter activity
GO:1901618 organic hydroxy compound transmembrane transporter activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-2161517: Abacavir transmembrane transport
R-HSA-2161522: Abacavir transport and metabolism
R-HSA-1430728: Metabolism
R-HSA-549127: Organic cation transport
R-HSA-549132: Organic cation/anion/zwitterion transport
R-HSA-425407: SLC-mediated transmembrane transport
R-HSA-382551: Transmembrane transport of small molecules
R-HSA-425366: Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds
Summary
SymbolSLC22A3
Namesolute carrier family 22 (organic cation transporter), member 3
Aliases solute carrier family 22 (extraneuronal monoamine transporter), member 3; EMTH; EMT organic cation transport ......
Chromosomal Location6q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SLC22A3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolSLC22A3
Namesolute carrier family 22 (organic cation transporter), member 3
Aliases solute carrier family 22 (extraneuronal monoamine transporter), member 3; EMTH; EMT organic cation transport ......
Chromosomal Location6q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SLC22A3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSLC22A3
Namesolute carrier family 22 (organic cation transporter), member 3
Aliases solute carrier family 22 (extraneuronal monoamine transporter), member 3; EMTH; EMT organic cation transport ......
Chromosomal Location6q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SLC22A3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0030.996
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3510.702
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2780.709
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.910.125
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.0990.489
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.6720.728
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.6160.448
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.2020.306
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0710.955
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.3790.723
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.7240.585
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.990.00149
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SLC22A3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSLC22A3
Namesolute carrier family 22 (organic cation transporter), member 3
Aliases solute carrier family 22 (extraneuronal monoamine transporter), member 3; EMTH; EMT organic cation transport ......
Chromosomal Location6q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SLC22A3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSLC22A3
Namesolute carrier family 22 (organic cation transporter), member 3
Aliases solute carrier family 22 (extraneuronal monoamine transporter), member 3; EMTH; EMT organic cation transport ......
Chromosomal Location6q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SLC22A3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SLC22A3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSLC22A3
Namesolute carrier family 22 (organic cation transporter), member 3
Aliases solute carrier family 22 (extraneuronal monoamine transporter), member 3; EMTH; EMT organic cation transport ......
Chromosomal Location6q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SLC22A3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSLC22A3
Namesolute carrier family 22 (organic cation transporter), member 3
Aliases solute carrier family 22 (extraneuronal monoamine transporter), member 3; EMTH; EMT organic cation transport ......
Chromosomal Location6q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SLC22A3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSLC22A3
Namesolute carrier family 22 (organic cation transporter), member 3
Aliases solute carrier family 22 (extraneuronal monoamine transporter), member 3; EMTH; EMT organic cation transport ......
Chromosomal Location6q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SLC22A3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSLC22A3
Namesolute carrier family 22 (organic cation transporter), member 3
Aliases solute carrier family 22 (extraneuronal monoamine transporter), member 3; EMTH; EMT organic cation transport ......
Chromosomal Location6q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SLC22A3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.